Substrates of multidrug resistance-associated proteins block the cystic fibrosis transmembrane conductance regulator chloride channel.
1. The effects of physiological substrates of multidrug resistance-associated proteins (MRPs) on cystic fibrosis transmembrane conductance regulator (CFTR) Cl- channel currents were examined using patch clamp recording from CFTR-transfected mammalian cell lines. 2. Two MRP substrates, taurolithocholate-3-sulphate (TLCS) and beta-estradiol 17-(beta-D-glucuronide) (E217betaG) caused a voltage-dependent block of macroscopic CFTR Cl- currents when applied to the intracellular face of excised membrane patches, with mean apparent dissociation constants (KDs) of 96+/-10 and 563+/-103 microM (at 0 mV) respectively. The unconjugated bile salts taurocholate and cholate were also effective CFTR channel blockers under these conditions, with KDs of 453+/-44 and 3760+/-710 microM (at 0 mV) respectively. 3. Reducing the extracellular Cl- concentration from 154 to 20 mM decreased the KD for block intracellular TLCS to 54+/-1 microM, and also significantly reduced the voltage dependence of block, by suggesting that TLCS blocks Cl- permeation through CFTR by binding within the channel pore. 4. Intracellular TLCS reduced the apparent amplitude of CFTR single channel currents, suggesting that the duration of block is very fast compared to the gating of the channel. 5. The apparent affinity of block by TLCs is comparable to that of other well-known CFTR channel blockers, suggesting that MRP substrates may comprise a novel class of probes of the CFTR channel pore. 6. These results also suggest that the related proteins CFTR and MRP may share a structurally similar anion binding site at the cytoplasmic face of the membrane.
Linsdell
P
P
Department of Physiology, McGill University, Montréal, Québec, Canada. linsdell@physio.mcgill.ca
Hanrahan
J W
JW
D018528:ATP-Binding Cassette Transporters / Q000378:metabolism*; D000818:Animals; D016466:CHO Cells; D002121:Calcium Channel Blockers / Q000494:pharmacology; D002712:Chlorides / Q000494:pharmacology; D020355:Cholates / Q000494:pharmacology; D006224:Cricetinae; D019005:Cystic Fibrosis Transmembrane Conductance Regulator / Q000037:antagonists & inhibitors*; D004305:Dose-Response Relationship, Drug; D004558:Electric Stimulation; D004958:Estradiol / Q000378:metabolism / Q000494:pharmacology*; D005905:Glyburide / Q000494:pharmacology; D008564:Membrane Potentials / Q000187:drug effects; D027425:ATP-Binding Cassette, Sub-Family C Proteins; D013267:Stilbenes / Q000494:pharmacology; D013656:Taurocholic Acid / Q000494:pharmacology; D013658:Taurolithocholic Acid / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology; D062367:ortho-Aminobenzoates / Q000494:pharmacology
D018528:ATP-Binding Cassette Transporters; D002121:Calcium Channel Blockers; D002712:Chlorides; D020355:Cholates; D019005:Cystic Fibrosis Transmembrane Conductance Regulator; D004958:Estradiol; D005905:Glyburide; D027425:ATP-Binding Cassette, Sub-Family C Proteins; D013267:Stilbenes; D013656:Taurocholic Acid; D013658:Taurolithocholic Acid; D062367:ortho-Aminobenzoates; C066776:taurolithocholic acid 3-sulfate; C022306:4,4'-dinitro-2,2'-stilbenedisulfonic acid; C001209:fenamic acid